GovChime
Notice ID: 86e139730dfa44fbbcdadd0f048914b0Presolicitation

Notice of Intent - Sole Source to PEPperPRINT GmbH

Archived on May 7, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM UTC−04:00
Posted
April 28, 2020
Notice type
Presolicitation
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION

Notice details

Office
FDA OFFICE OF ACQ GRANT SVCS
Last updated
Sep 9, 2025

Identifiers

Solicitation number
FDA-NOI-SS-1226443
Notice ID
86e139730dfa44fbbcdadd0f048914b0

Description

The U.S. Food & Drug Administration (FDA) intends to issue a Sole Source follow-on award to the PEPperPRINT GmbH for continuing existing validation studies. The Government intends to issue a sole source award in accordance with FAR 6.302-1, only one responsible source and no other will satisfy the agency requirements for the above stated service. FDA aims to provide tools to enable the development of assays that can provide unambiguous diagnosis of recent vs. past ZIKV infection through peptide-specific differentiation of IgM or IgG responses. These specific peptides will also help distinguishing ZIKV from its closely related viruses. The scope of the existing work is to continue ongoing validation studies which was started in 2016 under contract number 1U01FD006279. Peptides obtained by preliminary screening of full viral proteomes in research project were more numerous than expected due to underestimation of cross-reactivity. Due to the restriction imposed by the available funds, only partial count of the peptides obtained in the discovery screening were selected for the validation studies. In 2019, a first validation step study was conducted to continue the studies of the remainder of the peptides already identified in the original screening stage. Under this requirement, FDA is requesting to complete the final validation of about the remainder of the peptides. PEPperPRINT GmbH has previously conducted the validation studies for this requirement under the previous FDA contract. This is continuation of the same research project and so the work will be continued by the same company. The specimens used in the study were characterized for IgM/IgG antibodies against the virus under study by FDA cleared/ authorized assays as a first choice. This requirement aims to perform comparative proteome-wide epitope mapping analyses of ZIKV and other related viruses specific epitopes with single amino acid resolution. This will be a firm fixed price award.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:FDA-NOI-SS-1226443
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentApr 28, 2020

    Notice of Intent - Sole Source to PEPperPRINT GmbH

    Notice 86e139730dfa44fbbcdadd0f048914b0 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

FDA-NOI-SS-1226443

Archive Date

May 7, 2020

Office Address

Beltsville, MD, 20705